Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120
about
Pathogenesis of human immunodeficiency virus infectionHIV-1 entry inhibitors: an overviewHIV-1 entry inhibitors: recent development and clinical useStructure of an unliganded simian immunodeficiency virus gp120 coreLiposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells.Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.An initial in vitro investigation into the potential therapeutic use of SupT1 cells to prevent AIDS in HIV-seropositive individualsMultiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine seraEnhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein.Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid)Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency virusesCD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry.Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1.Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies.Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor bindingImmune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain.SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Is a pacific coexistence between virus and host the unexploited path that may lead to an HIV functional cure?Role of human CD4 D1D2 domain in HIV-1 infection.Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor.Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection.Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker
P2860
Q24634681-793A0F66-234F-4A5A-A958-526D7952684DQ24645525-B6744D8B-DEFB-43A1-A062-3CE3805F2978Q27003887-5B8C503E-0D66-420D-BE3E-F01F8E443F69Q29616089-3F0FF5CD-61B8-4CA1-8C41-1A41B9D7BEF2Q33637970-62930D43-39FC-42D3-9691-E94222CF3093Q33841969-4937CC3E-21E2-431B-8D7D-DF5AF30AB1A8Q33843345-2F38EB29-957C-4A9E-A015-4BB375FE4CB3Q33851094-F5021C9B-9233-44D8-98B7-AEDF3E5F019BQ34304964-DA05530F-E119-48A7-BFE7-DA580FAA21EAQ35105006-12F1D138-BF45-43A2-B328-7B0CA44B044EQ35828529-1652F1D4-49C4-40DD-AE5F-D2DE284E5130Q35833979-3555D55A-C07D-469F-92A3-ABB3A70E6D42Q35838613-8735FE57-4647-4585-8234-6375CAD5E993Q35841780-BC586E36-BFB0-4F4C-908B-99A02775FA4BQ35848446-91A16F2E-64E3-49ED-B9C9-B85862E58B31Q35849408-882B77F5-0842-428A-9F1C-8DFC8237D6E1Q35868205-013106FA-33C9-44C3-87D6-D9BCBA62C71CQ35876191-01BC640B-A4B6-4926-B5BF-1612496CE41FQ35886254-DF2765A2-D2FE-48B6-BB66-0B2C57BDA411Q36334029-A0B57261-C50F-4286-B156-CF19346A63E3Q36624656-33163765-3705-44FA-B858-51E9CDF9CBAAQ36628256-9E0000EE-305C-433D-879A-DE0D359AA3A0Q36629914-B0C45D8D-530D-47B6-B5B7-550DE43D69A0Q36632478-1586C514-0E5B-45B0-AB12-938F8B0BA9A5Q36643604-6D98B816-C3BF-4A65-9AC2-21257035AA75Q36655317-2D8E1F77-F21C-4F86-9210-DA9D8E96B1F0Q36655438-B0710039-B27E-4AD4-9C48-23B05679FECAQ36721188-84732403-99A0-47D1-A2EF-8EF4AC69DDBDQ37061926-E3F2504A-F339-4B7A-B834-D9E2C587581FQ38076139-E79A79CE-58C8-4575-B3B2-FAFC54C1E6C7Q39190552-EAE1778A-C44E-40DC-B268-1E3F0658F674Q39223730-AADA1F21-61F2-4176-B49E-78FA9FC39BF3Q39313957-2D9EBCD8-2901-4865-B4BC-0EB08D0E4B80Q39359591-98892B95-A3BC-4B89-9FD7-35C2D877E11EQ39577692-64E0B66D-5E28-468D-903C-034762F94052Q39868309-A5BA5235-157F-4C80-B0D9-E5420B49A9B7Q39868495-576E3766-1B7B-44D4-B27F-1CEAD1BAE5CBQ40433970-793563B8-6126-4138-9D72-7003388402DDQ40883803-3B94FBA4-C378-4BA7-ACD1-4533FA6C8254
P2860
Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Resistance of primary isolates ...... al envelope glycoprotein gp120
@en
type
label
Resistance of primary isolates ...... al envelope glycoprotein gp120
@en
prefLabel
Resistance of primary isolates ...... al envelope glycoprotein gp120
@en
P2093
P2860
P356
P1476
Resistance of primary isolates ...... al envelope glycoprotein gp120
@en
P2093
DeMarinis J
Pepinsky RB
Schooley R
P2860
P304
P356
10.1073/PNAS.89.4.1335
P407
P577
1992-02-01T00:00:00Z